Drug Profile
Tinidazole
Alternative Names: TindamaxLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Presutti Laboratories LLC
- Developer Mission Pharmacal
- Class Antibacterials; Antiprotozoals; Nitroimidazoles
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Amoebiasis; Amoebic liver abscess; Bacterial vaginosis; Giardiasis; Trichomoniasis
Most Recent Events
- 24 May 2007 Registered for Bacterial vaginosis in USA (PO)
- 17 Aug 2006 Preregistration for Bacterial vaginosis in USA (PO)
- 17 Aug 2006 Mission Pharmacal has filed a sNDA for a new indication - the treatment of patients with Bacterial vaginosis in USA